Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 19, 2009

Royal DSM Makes $110M Investment in NCPC and Creates Three Joint Ventures

Royal DSM Makes $110M Investment in NCPC and Creates Three Joint Ventures

Royal and NCPC create three joint ventures in China

  • Royal DSM inked contracts with North China Pharmaceutical Group (NCPC) totaling $110 million to invest in a 10% stake of NCPC and create two anti-infective joint ventures and one nutrition venture. DSM will hold a 51% majority in the two anti-infective ventures while holding a 30% share in the nutrition production venture.

    "This serves key strategic targets: strengthening our DSM nutritional products as well as our DSM anti-infectives portfolio and expanding our presence in the emerging Chinese market," says Jan Zuidam, deputy chairman of DSM. "The overall strategic partnership with NCPC provides an accelerated growth path into the Chinese market and will contribute to our target of $1.5 billion sales in China in 2010." DSM's 2008 revenue in China was about $1.1 billion.

    The therapeutic venture will focus on active pharmaceuticals and intermediates, and the nutrition entity will deal with vitamin C. Both are expected to be implemented in the second half. The joint operations will combine DSM's technology and management resources with NCPC's factories, producing Vitamin C and beta lactam antibiotics, as well as a sales force for antibiotics.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »